Personalized Medicines in Oncology Market - Forecast(2022 - 2027)

Report Code: HCR 0097 Report Format: PDF + Excel

Personalized Medicines in Oncology Market Overview

Personalized Medicines in Oncology Market size is estimated to reach $272.1 billion by 2027, growing at a CAGR of 10.6% during the forecast period 2022-2027. Personalized medicines are also demarcated as precision medicines which are fabricated on the basis of molecular profiling and medical imaging of individual patients to enlarge the effectiveness of cancer treatments. The principal objective behind the usage of precision medicine or predictive biomarker is to customize the correct treatment for the correct patient. Several contemporary sequencing techniques such as cancer genome sequencing and next-generation sequencing help study the genes and provide genomic data. Additionally, measures like biomarkers play a significant role in the development of personalized medicines as they are proficient in identifying the patient’s response to certain medical drugs. Chemotherapy, immunotherapy, hormonal therapy, and others are commonly used in treating patients afflicted with different types of cancers. However, the bodies of some patients do not adapt to particular treatments such as chemotherapy and eventually worsens their situation. Therefore, precision medicines make it easy for doctors to understand which therapy should a person undergo to avoid further health complications. Accruing cases of cancer worldwide is one of the prominent factors set to drive the growth of Personalized Medicines in the Oncology Market for the period 2022-2027.

Report Coverage

The report: “Personalized Medicines in Oncology Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Personalized Medicines in the Oncology Market.

By Technology: Genome sequencing, In situ hybridization, Next-generation sequencing (NGS), Microarray, PCR, and others.
By Use/Application: Targeted therapy, Pharmacogenomics.
By Cancer Type: Endometrial cancer, Breast cancer, Esophageal cancer, Prostate cancer, Lung cancer, Neuroendocrine tumor, Colorectal cancer, Cervical cancer, Blood cancer, and others.
By End User: Cancer research centers, Hospitals, Diagnostics facilities, and Pharmaceutical and Biotechnology Companies.
By Geography: North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, and Rest of South America) and Rest of World (the Middle East and Africa).

Key Takeaways

  • Geographically, the North America Personalized Medicines in Oncology Market accounted for the highest revenue share in 2021. It is owing to the steep presence of robust Med-tech companies often supplemented by backings of both government and private venture capitalists. However, Asia-Pacific is poised to dominate the market over the period 2022-2027. It is owing to the steep rise in research and development activities especially pertaining to cancer.
  • Proliferating geriatric population is said to be a preeminent driver driving the growth of Personalized Medicines in the Oncology Market. The extortionate price of cancer treatments is said to reduce the market growth.
  • Detailed analysis on the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the Personalized Medicines in Oncology Market report.

    Personalized Medicines in Oncology Market- Geography (%) for 2021

    Personalized Medicines in Oncology Market

For More Details on This Report - Request for Sample

Personalized Medicines in Oncology Market Segment Analysis - By Cancer Type

The Personalized Medicines in Oncology Market based on the cancer type can be further segmented into endometrial cancer, breast cancer, esophageal cancer, prostate cancer, lung cancer, neuroendocrine tumor, colorectal cancer, cervical cancer, blood cancer, and others. The Breast cancer segment held the largest share in 2021. The growth is owing to widescale prevalence among both men and women around the globe. Breast cancer is 2nd biggest reason behind the deaths of women in the US. Moreover, it claimed more than 600,000 lives in 2020. Therefore, the demand for precision medicines in the treatment of breast cancer is swelling. These medicines help in tailoring a perfect treatment by studying the genetic mutation in cancer cells and the genetic makeup that a person is born with. Nevertheless, the lung cancer segment is estimated to be the fastest-growing segment with a CAGR of 11.3% over the forecast period 2022-2027. This growth is owing to the heightening prevalence of lung cancer. Smoke from vehicles, CO2 emission from industries, burning plastic items, and augmenting smoking trends are prime factors increasing the spread of lung cancer worldwide. 

Personalized Medicines in Oncology Market Segment Analysis - By End User

The Personalized Medicines in Oncology Market based on end-user can be further segmented into hospitals, diagnostics facilities, and research institutions. The hospital segment held the largest share in 2021. The growth is owing to the far-reaching presence of hospitals as compared to other medical facilities. The hospitals are the first point of contact for the people suffering from such life-threatening illnesses. In addition to that, hospitals extend several benefits to patients such as 24/7 patient care, top-of-the-line medical professionals, the availability of vital tools and techniques to execute cancer procedures. Putting aside hospitals the cancer treatment centers also provide better quality treatment to patients, but their lower presence and expensive treatments are the biggest obstructions in their growth.

Moreover, the pharmaceutical and biotechnology companies segment is estimated to be the fastest-growing with a CAGR of 11.6% over the forecast period 2022-2027. The growth is owing to the robust backing of various governments and private venture capitalists. For example, mRNA vaccines which have been heavily deployed for COVID-19 vaccinations have been long under trial to eliminate cancer cells. Pfizer and BioTech are under phase-2 experimental trial for their vaccine which can target the cancer cells. Moreover, the vaccine would target the protein on the tumor cell.

Personalized Medicines in Oncology Market Segment Analysis - By Geography

The Personalized Medicines in Oncology Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held the largest share with 42% of the overall market in 2021. The growth in this segment is owing to the factors such as the high pervasiveness of breast and lung cancer in the US. Besides, to curve the rising demand North American nations like Canada, US have world-class healthcare infrastructure which includes state-of-the-art research laboratories and hospitals like Mayo clinic. Due to high salary offers the US have proper availability of top-flight doctors and researcher Moreover, high health awareness among people and decent purchasing capacity to undergo expensive cancer treatments is a preeminent factor in the growth of the respective market in the North American continent. Further, the US experiences a cost worth of $208.9 billion for cancer care, which has increased by around 10% from the year 2015.

However, Asia-Pacific is expected to be the fastest-growing segment over the forecast period 2022-2027. This growth is owing to intensification in the spread of cancer due to augmenting the old-age population. Around 18.7% of the total population of China is aging above 60 years and the number is plunging upward at a swift pace. On another hand, several south Asian states including China and India have the worst air quality in the world which is prompting the overall prevalence of cancer in both teenagers and adults.

Personalized Medicines in Oncology Market Drivers

Broadening research and development activities and advancement in technologies is Anticipated to Boost Product Demand

The presence of technologies such as Next-generation sequencing (NGS), FISH, and Genomic sequencing play their noteworthy contribution in the research and synthesis of prescribed medicines. In addition to that, escalating number of mergers and acquisitions market players in order to gain a competitive advantage over their competitors are helping the market in abundant ways. Moreover, companies are increasing spendings on research activities to fabricate more effective drugs and techniques. For instance, Pfizer’s research and development spending has touched almost $10 billion.

Heightening the number of cancer cases is Expected to Boost Product Demand

The extensive incidences of cancer are the foremost driver in the growing demand for personalized medicines. There are numerous reasons behind people diagnosing with cancer. Some of them are; worsening air quality, cigarette smoking, growing elderly population, the smoke of unburnt vehicle fuel, and contaminated water.  ascribing to an upsurge in smoking the number of people inflicted with it is augmenting. It’s the main reason behind cancer deaths around the globe. In 2021 around 1.9 million cases of cancer were found which eventually led to more than 600,000 fatalities. Moreover, over 130,000 deaths are reported every year in the US due to lung cancer. Besides, a major faction of the world population is turning old. The elderly population has reached over 700 million in 2021 and is estimated to reach 2 billons before long.

Personalized Medicines in Oncology Market Challenges

Lack of awareness about precision medicines, expensive cancer treatments are Anticipated to Hamper Market Growth

Cancer treatments don’t come easy. With growing success rates of personalized drugs, their prices are elevating also. People are supposed to spend a fortune if they want to cure themselves by undergoing various curative procedures. Breast cancer has the most expensive treatments. Even the average treatment can cost a person up to $100,000 which the majority of the people cannot afford. Moreover, lack of consciousness among people about personalized medicines can be also cripple the growth of the personalized medicines market. 

Personalized Medicines in Oncology Market Competitive Landscape:

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Personalized Medicines in Oncology Market. Key companies of this market are-

  1. Abbott
  2. Exact Science Corporation
  3. GE Healthcare
  4. Illumina
  5. Celera Diagnostics
  6. Biogen
  7. Decode Genetics
  8. Danaher Corporation
  9. Novartis
  10. Genelex Corporation

Recent Developments/Product Launches:

  • In December 2021, Excellent outcomes for new leukemia and lymphoma drug have been found by the researchers. The first-ever clinical trial of a blood cancer drug known as LOXO-305 or Pirtobrutinib was conducted. The trials took place on people suffering from multiple forms of leukemia and lymphoma, which also included chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle lymphoma as well as other forms of non-Hodgkin lymphoma. Furthermore, the drug has been focused on people who have stopped responding.
  • In September 2021, Pfizer-BioNTech launched a serosurvey to find out the efficacy of vaccines on the people afflicted and fighting with cancer. The results so far have been reassuring in many aspects. The researchers had compared COVID-19 antibody levels between two groups right after the second dose and then after 6 months. After the six months, post-dose of vaccine, 79% of the people receiving treatment for cancer had COVID-19 antibodies while 84% of the healthcare workers who have had no cancer maintained high antibody levels. Owing to the said study, people can be encouraged for vaccination.
  • In May 2021, First-ever KRAS Inhibitor has been approved for an “undruggable” lung cancer target. The name of the targeted medicine has been named Sotorasib. Further, the treatment of certain advanced non-small cell lung cancers in patients who have already received at least one other treatment. The approval was based on clinical trials co-led by MSK medical oncologist Bob Li. This approval marks a major milestone in targeted therapies and changes the treatment paradigm for patients with KRAS-G12C-mutated non-small cell lung cancer.

Relevant Reports:

Cancer Testing/Screening Market – Forecast (2022 - 2027)
Report Code: HCR 0078

Cancer Immunotherapy Market – Forecast (2022 - 2027)
Report Code: HCR 0197

For more Lifesciences and Healthcare related reports, please click here

1. Personalized Medicines in Oncology Market Overview
    1.1 Definitions and Scope
2. Personalized Medicines in Oncology Market- Executive Summary
3. Personalized Medicines in Oncology Market – Market Landscape
    3.1 Company Benchmarking- Key Companies
    3.2 Key Company Financial Analysis
    3.3 Market Share Analysis
    3.4 Patent Analysis
    3.5 Pricing Analysis (Comparison of General Price Offerings in the Market)
4. Personalized Medicines in Oncology Market – Startup Company Scenario (Premium)
    4.1 Investment
    4.2 Revenue
    4.3 Venture Capital and Funding Scenario
5. Personalized Medicines in Oncology Market – Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Scenario
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Personalized Medicines in Oncology Market - Market Forces
    6.1 Market Drivers
    6.2 Market Constraints
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Personalized Medicines in Oncology Market – By Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle Analysis
8. Personalized Medicines in Oncology Market- By Technology (Market Size –$Million/$Billion) 
    8.1 Genome Sequencing
    8.2 In-Situ Hybridization
    8.3 NGS
    8.4 Microarray
    8.5 PCR
    8.6 Others
9. Personalized Medicines in Oncology Market- By Application (Market Size –$Million/$Billion) 
    9.1 Targeted Therapy
    9.2 Pharmacogenomics
10. Personalized Medicines in Oncology Market- By Cancer Type (Market Size –$Million/$Billion) 
    10.1 Endometrial Cancer
    10.2 Breast Cancer
    10.3 Esophageal Cancer
    10.4 Prostate Cancer
    10.5 Lung Cancer
    10.6 Neuroendocrine Cancer
    10.7 Colorectal Cancer
    10.8 Cervical Cancer
    10.9 Blood Cancer
    10.10 Others
11. Personalized Medicines in Oncology Market- By End Users (Market Size –$Million/$Billion) 
    11.1 Cancer Research Centers
    11.2 Pharmaceutical and Biotechnology Companies
    11.3 Hospital and Private Clinics
    11.4 Others
12. Personalized Medicines in Oncology Market - By Geography (Market Size -$Million/Billion)
    12.1 North America
        12.1.1 U.S
        12.1.2 Canada
        12.1.3 Mexico
    12.2 Europe
        12.2.1 Germany
        12.2.2 France
        12.2.3 UK
        12.2.4 Italy
        12.2.5 Spain
        12.2.6 Russia
        12.2.7 Rest of Europe
    12.3 Asia-Pacific
        12.3.1 China
        12.3.2 Japan
        12.3.3 South Korea
        12.3.4 India
        12.3.5 Australia & New Zealand
        12.3.6 Rest of APAC
    12.4 South America
        12.4.1 Brazil
        12.4.2 Argentina
        12.4.3 Chile
        12.4.4 Colombia
        12.4.5 Rest of South America
    12.5 Rest of the World
        12.5.1 Middle East
        12.5.2 Africa
13. Personalized Medicines in Oncology Market - Market Entropy
    13.1 New product launches
    13.2 M&A's, collaborations, JVs, and partnerships
14. Personalized Medicines in Oncology Market – Industry Competition Landscape (Premium)
    14.1 Market Share Analysis
        14.1.1 Global Market Share – Key Companies
        14.1.2 Market Share by Region – Key Companies
        14.1.3 Market Share by Countries – Key Companies
    14.2 Competition Matrix
    14.3 Best Practices for Companies
15. Personalized Medicines in Oncology Market – Key Company List by Country Premium (Premium)
16. Personalized Medicines in Oncology Market - Company Analysis
    16.1 Company 1
    16.2 Company 2
    16.3 Company 3
    16.4 Company 4
    16.5 Company 5
    16.6 Company 6
    16.7 Company 7
    16.8 Company 8
    16.9 Company 9
    16.10 Company 10
"*Financials would be provided on a best-efforts basis for private companies"
List of Tables

Table 1: Personalized Medicines In Oncology Market Overview 2021-2026
Table 2: Personalized Medicines In Oncology Market Leader Analysis 2018-2019 (US$)
Table 3: Personalized Medicines In Oncology Market Product Analysis 2018-2019 (US$)
Table 4: Personalized Medicines In Oncology Market End User Analysis 2018-2019 (US$)
Table 5: Personalized Medicines In Oncology Market Patent Analysis 2013-2018* (US$)
Table 6: Personalized Medicines In Oncology Market Financial Analysis 2018-2019 (US$)
Table 7: Personalized Medicines In Oncology Market Driver Analysis 2018-2019 (US$)
Table 8: Personalized Medicines In Oncology Market Challenges Analysis 2018-2019 (US$)
Table 9: Personalized Medicines In Oncology Market Constraint Analysis 2018-2019 (US$)
Table 10: Personalized Medicines In Oncology Market Supplier Bargaining Power Analysis 2018-2019 (US$)
Table 11: Personalized Medicines In Oncology Market Buyer Bargaining Power Analysis 2018-2019 (US$)
Table 12: Personalized Medicines In Oncology Market Threat of Substitutes Analysis 2018-2019 (US$)
Table 13: Personalized Medicines In Oncology Market Threat of New Entrants Analysis 2018-2019 (US$)
Table 14: Personalized Medicines In Oncology Market Degree of Competition Analysis 2018-2019 (US$)
Table 15: Personalized Medicines In Oncology Market Value Chain Analysis 2018-2019 (US$)
Table 16: Personalized Medicines In Oncology Market Pricing Analysis 2021-2026 (US$)
Table 17: Personalized Medicines In Oncology Market Opportunities Analysis 2021-2026 (US$)
Table 18: Personalized Medicines In Oncology Market Product Life Cycle Analysis 2021-2026 (US$)
Table 19: Personalized Medicines In Oncology Market Supplier Analysis 2018-2019 (US$)
Table 20: Personalized Medicines In Oncology Market Distributor Analysis 2018-2019 (US$)
Table 21: Personalized Medicines In Oncology Market Trend Analysis 2018-2019 (US$)
Table 22: Personalized Medicines In Oncology Market Size 2018 (US$)
Table 23: Personalized Medicines In Oncology Market Forecast Analysis 2021-2026 (US$)
Table 24: Personalized Medicines In Oncology Market Sales Forecast Analysis 2021-2026 (Units)
Table 25: Personalized Medicines In Oncology Market, Revenue & Volume, By Tumore Type, 2021-2026 ($)
Table 26: Personalized Medicines In Oncology Market By Tumore Type, Revenue & Volume, By Genomics, 2021-2026 ($)
Table 27: Personalized Medicines In Oncology Market By Tumore Type, Revenue & Volume, By Proteomics, 2021-2026 ($)
Table 28: Personalized Medicines In Oncology Market By Tumore Type, Revenue & Volume, By Metabolomics, 2021-2026 ($)
Table 29: Personalized Medicines In Oncology Market By Tumore Type, Revenue & Volume, By Epigenetics, 2021-2026 ($)
Table 30: Personalized Medicines In Oncology Market, Revenue & Volume, By Service, 2021-2026 ($)
Table 31: Personalized Medicines In Oncology Market By Service, Revenue & Volume, By Molecular Oncopathology, 2021-2026 ($)
Table 32: Personalized Medicines In Oncology Market By Service, Revenue & Volume, By Genome Diagnostics, 2021-2026 ($)
Table 33: Personalized Medicines In Oncology Market By Service, Revenue & Volume, By Radiation Therapy, 2021-2026 ($)
Table 34: Personalized Medicines In Oncology Market By Service, Revenue & Volume, By Oncology Testing, 2021-2026 ($)
Table 35: Personalized Medicines In Oncology Market By Service, Revenue & Volume, By Chemotherapy, 2021-2026 ($)
Table 36: Personalized Medicines In Oncology Market, Revenue & Volume, By Technology, 2021-2026 ($)
Table 37: Personalized Medicines In Oncology Market By Technology, Revenue & Volume, By Next-Generation Sequencing, 2021-2026 ($)
Table 38: Personalized Medicines In Oncology Market By Technology, Revenue & Volume, By Fluorescence/ Chromogenic In Situ Hybridization, 2021-2026 ($)
Table 39: Personalized Medicines In Oncology Market By Technology, Revenue & Volume, By Immunohistochemistry, 2021-2026 ($)
Table 40: Personalized Medicines In Oncology Market By Technology, Revenue & Volume, By Microarray, 2021-2026 ($)
Table 41: Personalized Medicines In Oncology Market By Technology, Revenue & Volume, By Quantitative PCR, 2021-2026 ($)
Table 42: Personalized Medicines In Oncology Market, Revenue & Volume, By Occurrence, 2021-2026 ($)
Table 43: Personalized Medicines In Oncology Market By Occurrence, Revenue & Volume, By Colorectal/ stomach/ esophageal, 2021-2026 ($)
Table 44: Personalized Medicines In Oncology Market By Occurrence, Revenue & Volume, By Ovarian, 2021-2026 ($)
Table 45: Personalized Medicines In Oncology Market By Occurrence, Revenue & Volume, By Lung, 2021-2026 ($)
Table 46: Personalized Medicines In Oncology Market By Occurrence, Revenue & Volume, By Brest, 2021-2026 ($)
Table 47: Personalized Medicines In Oncology Market By Occurrence, Revenue & Volume, By Sarcoma, 2021-2026 ($)
Table 48: Personalized Medicines In Oncology Market, Revenue & Volume, By End User, 2021-2026 ($)
Table 49: Personalized Medicines In Oncology Market By End User, Revenue & Volume, By Research Centers, 2021-2026 ($)
Table 50: Personalized Medicines In Oncology Market By End User, Revenue & Volume, By Governmental Institutions, 2021-2026 ($)
Table 51: Personalized Medicines In Oncology Market By End User, Revenue & Volume, By Hospitals, 2021-2026 ($)
Table 52: North America Personalized Medicines In Oncology Market, Revenue & Volume, By Tumore Type, 2021-2026 ($)
Table 53: North America Personalized Medicines In Oncology Market, Revenue & Volume, By Service, 2021-2026 ($)
Table 54: North America Personalized Medicines In Oncology Market, Revenue & Volume, By Technology, 2021-2026 ($)
Table 55: North America Personalized Medicines In Oncology Market, Revenue & Volume, By Occurrence, 2021-2026 ($)
Table 56: North America Personalized Medicines In Oncology Market, Revenue & Volume, By End User, 2021-2026 ($)
Table 57: South america Personalized Medicines In Oncology Market, Revenue & Volume, By Tumore Type, 2021-2026 ($)
Table 58: South america Personalized Medicines In Oncology Market, Revenue & Volume, By Service, 2021-2026 ($)
Table 59: South america Personalized Medicines In Oncology Market, Revenue & Volume, By Technology, 2021-2026 ($)
Table 60: South america Personalized Medicines In Oncology Market, Revenue & Volume, By Occurrence, 2021-2026 ($)
Table 61: South america Personalized Medicines In Oncology Market, Revenue & Volume, By End User, 2021-2026 ($)
Table 62: Europe Personalized Medicines In Oncology Market, Revenue & Volume, By Tumore Type, 2021-2026 ($)
Table 63: Europe Personalized Medicines In Oncology Market, Revenue & Volume, By Service, 2021-2026 ($)
Table 64: Europe Personalized Medicines In Oncology Market, Revenue & Volume, By Technology, 2021-2026 ($)
Table 65: Europe Personalized Medicines In Oncology Market, Revenue & Volume, By Occurrence, 2021-2026 ($)
Table 66: Europe Personalized Medicines In Oncology Market, Revenue & Volume, By End User, 2021-2026 ($)
Table 67: APAC Personalized Medicines In Oncology Market, Revenue & Volume, By Tumore Type, 2021-2026 ($)
Table 68: APAC Personalized Medicines In Oncology Market, Revenue & Volume, By Service, 2021-2026 ($)
Table 69: APAC Personalized Medicines In Oncology Market, Revenue & Volume, By Technology, 2021-2026 ($)
Table 70: APAC Personalized Medicines In Oncology Market, Revenue & Volume, By Occurrence, 2021-2026 ($)
Table 71: APAC Personalized Medicines In Oncology Market, Revenue & Volume, By End User, 2021-2026 ($)
Table 72: Middle East & Africa Personalized Medicines In Oncology Market, Revenue & Volume, By Tumore Type, 2021-2026 ($)
Table 73: Middle East & Africa Personalized Medicines In Oncology Market, Revenue & Volume, By Service, 2021-2026 ($)
Table 74: Middle East & Africa Personalized Medicines In Oncology Market, Revenue & Volume, By Technology, 2021-2026 ($)
Table 75: Middle East & Africa Personalized Medicines In Oncology Market, Revenue & Volume, By Occurrence, 2021-2026 ($)
Table 76: Middle East & Africa Personalized Medicines In Oncology Market, Revenue & Volume, By End User, 2021-2026 ($)
Table 77: Russia Personalized Medicines In Oncology Market, Revenue & Volume, By Tumore Type, 2021-2026 ($)
Table 78: Russia Personalized Medicines In Oncology Market, Revenue & Volume, By Service, 2021-2026 ($)
Table 79: Russia Personalized Medicines In Oncology Market, Revenue & Volume, By Technology, 2021-2026 ($)
Table 80: Russia Personalized Medicines In Oncology Market, Revenue & Volume, By Occurrence, 2021-2026 ($)
Table 81: Russia Personalized Medicines In Oncology Market, Revenue & Volume, By End User, 2021-2026 ($)
Table 82: Israel Personalized Medicines In Oncology Market, Revenue & Volume, By Tumore Type, 2021-2026 ($)
Table 83: Israel Personalized Medicines In Oncology Market, Revenue & Volume, By Service, 2021-2026 ($)
Table 84: Israel Personalized Medicines In Oncology Market, Revenue & Volume, By Technology, 2021-2026 ($)
Table 85: Israel Personalized Medicines In Oncology Market, Revenue & Volume, By Occurrence, 2021-2026 ($)
Table 86: Israel Personalized Medicines In Oncology Market, Revenue & Volume, By End User, 2021-2026 ($)
Table 87: Top Companies 2018 (US$)Personalized Medicines In Oncology Market, Revenue & Volume
Table 88: Product Launch 2018-2019Personalized Medicines In Oncology Market, Revenue & Volume
Table 89: Mergers & Acquistions 2018-2019Personalized Medicines In Oncology Market, Revenue & Volume


List of Figures

Figure 1: Overview of Personalized Medicines In Oncology Market 2021-2026
Figure 2: Market Share Analysis for Personalized Medicines In Oncology Market 2018 (US$)
Figure 3: Product Comparison in Personalized Medicines In Oncology Market 2018-2019 (US$)
Figure 4: End User Profile for Personalized Medicines In Oncology Market 2018-2019 (US$)
Figure 5: Patent Application and Grant in Personalized Medicines In Oncology Market 2013-2018* (US$)
Figure 6: Top 5 Companies Financial Analysis in Personalized Medicines In Oncology Market 2018-2019 (US$)
Figure 7: Market Entry Strategy in Personalized Medicines In Oncology Market 2018-2019
Figure 8: Ecosystem Analysis in Personalized Medicines In Oncology Market 2018
Figure 9: Average Selling Price in Personalized Medicines In Oncology Market 2021-2026
Figure 10: Top Opportunites in Personalized Medicines In Oncology Market 2018-2019
Figure 11: Market Life Cycle Analysis in Personalized Medicines In Oncology Market
Figure 12: GlobalBy Tumore TypePersonalized Medicines In Oncology Market Revenue, 2021-2026 ($)
Figure 13: GlobalBy ServicePersonalized Medicines In Oncology Market Revenue, 2021-2026 ($)
Figure 14: GlobalBy TechnologyPersonalized Medicines In Oncology Market Revenue, 2021-2026 ($)
Figure 15: GlobalBy OccurrencePersonalized Medicines In Oncology Market Revenue, 2021-2026 ($)
Figure 16: GlobalBy End UserPersonalized Medicines In Oncology Market Revenue, 2021-2026 ($)
Figure 17: Global Personalized Medicines In Oncology Market - By Geography
Figure 18: Global Personalized Medicines In Oncology Market Value & Volume, By Geography, 2021-2026 ($) 
Figure 19: Global Personalized Medicines In Oncology Market CAGR, By Geography, 2021-2026 (%)
Figure 20: North America Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 21: US Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 22: US GDP and Population, 2018-2019 ($)
Figure 23: US GDP – Composition of 2018, By Sector of Origin
Figure 24: US Export and Import Value & Volume, 2018-2019 ($)
Figure 25: Canada Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 26: Canada GDP and Population, 2018-2019 ($)
Figure 27: Canada GDP – Composition of 2018, By Sector of Origin
Figure 28: Canada Export and Import Value & Volume, 2018-2019 ($)
Figure 29: Mexico Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 30: Mexico GDP and Population, 2018-2019 ($)
Figure 31: Mexico GDP – Composition of 2018, By Sector of Origin
Figure 32: Mexico Export and Import Value & Volume, 2018-2019 ($)
Figure 33: South America Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 34: Brazil Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 35: Brazil GDP and Population, 2018-2019 ($)
Figure 36: Brazil GDP – Composition of 2018, By Sector of Origin
Figure 37: Brazil Export and Import Value & Volume, 2018-2019 ($)
Figure 38: Venezuela Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 39: Venezuela GDP and Population, 2018-2019 ($)
Figure 40: Venezuela GDP – Composition of 2018, By Sector of Origin
Figure 41: Venezuela Export and Import Value & Volume, 2018-2019 ($)
Figure 42: Argentina Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 43: Argentina GDP and Population, 2018-2019 ($)
Figure 44: Argentina GDP – Composition of 2018, By Sector of Origin
Figure 45: Argentina Export and Import Value & Volume, 2018-2019 ($)
Figure 46: Ecuador Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 47: Ecuador GDP and Population, 2018-2019 ($)
Figure 48: Ecuador GDP – Composition of 2018, By Sector of Origin
Figure 49: Ecuador Export and Import Value & Volume, 2018-2019 ($)
Figure 50: Peru Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 51: Peru GDP and Population, 2018-2019 ($)
Figure 52: Peru GDP – Composition of 2018, By Sector of Origin
Figure 53: Peru Export and Import Value & Volume, 2018-2019 ($)
Figure 54: Colombia Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 55: Colombia GDP and Population, 2018-2019 ($)
Figure 56: Colombia GDP – Composition of 2018, By Sector of Origin
Figure 57: Colombia Export and Import Value & Volume, 2018-2019 ($)
Figure 58: Costa Rica Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 59: Costa Rica GDP and Population, 2018-2019 ($)
Figure 60: Costa Rica GDP – Composition of 2018, By Sector of Origin
Figure 61: Costa Rica Export and Import Value & Volume, 2018-2019 ($)
Figure 62: Europe Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 63: U.K Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 64: U.K GDP and Population, 2018-2019 ($)
Figure 65: U.K GDP – Composition of 2018, By Sector of Origin
Figure 66: U.K Export and Import Value & Volume, 2018-2019 ($)
Figure 67: Germany Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 68: Germany GDP and Population, 2018-2019 ($)
Figure 69: Germany GDP – Composition of 2018, By Sector of Origin
Figure 70: Germany Export and Import Value & Volume, 2018-2019 ($)
Figure 71: Italy Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 72: Italy GDP and Population, 2018-2019 ($)
Figure 73: Italy GDP – Composition of 2018, By Sector of Origin
Figure 74: Italy Export and Import Value & Volume, 2018-2019 ($)
Figure 75: France Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 76: France GDP and Population, 2018-2019 ($)
Figure 77: France GDP – Composition of 2018, By Sector of Origin
Figure 78: France Export and Import Value & Volume, 2018-2019 ($)
Figure 79: Netherlands Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 80: Netherlands GDP and Population, 2018-2019 ($)
Figure 81: Netherlands GDP – Composition of 2018, By Sector of Origin
Figure 82: Netherlands Export and Import Value & Volume, 2018-2019 ($)
Figure 83: Belgium Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 84: Belgium GDP and Population, 2018-2019 ($)
Figure 85: Belgium GDP – Composition of 2018, By Sector of Origin
Figure 86: Belgium Export and Import Value & Volume, 2018-2019 ($)
Figure 87: Spain Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 88: Spain GDP and Population, 2018-2019 ($)
Figure 89: Spain GDP – Composition of 2018, By Sector of Origin
Figure 90: Spain Export and Import Value & Volume, 2018-2019 ($)
Figure 91: Denmark Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 92: Denmark GDP and Population, 2018-2019 ($)
Figure 93: Denmark GDP – Composition of 2018, By Sector of Origin
Figure 94: Denmark Export and Import Value & Volume, 2018-2019 ($)
Figure 95: APAC Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 96: China Personalized Medicines In Oncology Market Value & Volume, 2021-2026
Figure 97: China GDP and Population, 2018-2019 ($)
Figure 98: China GDP – Composition of 2018, By Sector of Origin
Figure 99: China Export and Import Value & Volume, 2018-2019 ($)Personalized Medicines In Oncology Market China Export and Import Value & Volume, 2018-2019 ($)
Figure 100: Australia Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 101: Australia GDP and Population, 2018-2019 ($)
Figure 102: Australia GDP – Composition of 2018, By Sector of Origin
Figure 103: Australia Export and Import Value & Volume, 2018-2019 ($)
Figure 104: South Korea Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 105: South Korea GDP and Population, 2018-2019 ($)
Figure 106: South Korea GDP – Composition of 2018, By Sector of Origin
Figure 107: South Korea Export and Import Value & Volume, 2018-2019 ($)
Figure 108: India Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 109: India GDP and Population, 2018-2019 ($)
Figure 110: India GDP – Composition of 2018, By Sector of Origin
Figure 111: India Export and Import Value & Volume, 2018-2019 ($)
Figure 112: Taiwan Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 113: Taiwan GDP and Population, 2018-2019 ($)
Figure 114: Taiwan GDP – Composition of 2018, By Sector of Origin
Figure 115: Taiwan Export and Import Value & Volume, 2018-2019 ($)
Figure 116: Malaysia Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 117: Malaysia GDP and Population, 2018-2019 ($)
Figure 118: Malaysia GDP – Composition of 2018, By Sector of Origin
Figure 119: Malaysia Export and Import Value & Volume, 2018-2019 ($)
Figure 120: Hong Kong Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 121: Hong Kong GDP and Population, 2018-2019 ($)
Figure 122: Hong Kong GDP – Composition of 2018, By Sector of Origin
Figure 123: Hong Kong Export and Import Value & Volume, 2018-2019 ($)
Figure 124: Middle East & Africa Personalized Medicines In Oncology Market Middle East & Africa 3D Printing Market Value & Volume, 2021-2026 ($)
Figure 125: Russia Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 126: Russia GDP and Population, 2018-2019 ($)
Figure 127: Russia GDP – Composition of 2018, By Sector of Origin
Figure 128: Russia Export and Import Value & Volume, 2018-2019 ($)
Figure 129: Israel Personalized Medicines In Oncology Market Value & Volume, 2021-2026 ($)
Figure 130: Israel GDP and Population, 2018-2019 ($)
Figure 131: Israel GDP – Composition of 2018, By Sector of Origin
Figure 132: Israel Export and Import Value & Volume, 2018-2019 ($)
Figure 133: Entropy Share, By Strategies, 2018-2019* (%)Personalized Medicines In Oncology Market
Figure 134: Developments, 2018-2019*Personalized Medicines In Oncology Market
Figure 135: Company 1 Personalized Medicines In Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 136: Company 1 Personalized Medicines In Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 137: Company 1 Personalized Medicines In Oncology Market Net Sales Share, By Geography, 2018 (%)
Figure 138: Company 2 Personalized Medicines In Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 139: Company 2 Personalized Medicines In Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 140: Company 2 Personalized Medicines In Oncology Market Net Sales Share, By Geography, 2018 (%)
Figure 141: Company 3 Personalized Medicines In Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 142: Company 3 Personalized Medicines In Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 143: Company 3 Personalized Medicines In Oncology Market Net Sales Share, By Geography, 2018 (%)
Figure 144: Company 4 Personalized Medicines In Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 145: Company 4 Personalized Medicines In Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 146: Company 4 Personalized Medicines In Oncology Market Net Sales Share, By Geography, 2018 (%)
Figure 147: Company 5 Personalized Medicines In Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 148: Company 5 Personalized Medicines In Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 149: Company 5 Personalized Medicines In Oncology Market Net Sales Share, By Geography, 2018 (%)
Figure 150: Company 6 Personalized Medicines In Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 151: Company 6 Personalized Medicines In Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 152: Company 6 Personalized Medicines In Oncology Market Net Sales Share, By Geography, 2018 (%)
Figure 153: Company 7 Personalized Medicines In Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 154: Company 7 Personalized Medicines In Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 155: Company 7 Personalized Medicines In Oncology Market Net Sales Share, By Geography, 2018 (%)
Figure 156: Company 8 Personalized Medicines In Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 157: Company 8 Personalized Medicines In Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 158: Company 8 Personalized Medicines In Oncology Market Net Sales Share, By Geography, 2018 (%)
Figure 159: Company 9 Personalized Medicines In Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 160: Company 9 Personalized Medicines In Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 161: Company 9 Personalized Medicines In Oncology Market Net Sales Share, By Geography, 2018 (%)
Figure 162: Company 10 Personalized Medicines In Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 163: Company 10 Personalized Medicines In Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 164: Company 10 Personalized Medicines In Oncology Market Net Sales Share, By Geography, 2018 (%)
Figure 165: Company 11 Personalized Medicines In Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 166: Company 11 Personalized Medicines In Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 167: Company 11 Personalized Medicines In Oncology Market Net Sales Share, By Geography, 2018 (%)
Figure 168: Company 12 Personalized Medicines In Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 169: Company 12 Personalized Medicines In Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 170: Company 12 Personalized Medicines In Oncology Market Net Sales Share, By Geography, 2018 (%)
Figure 171: Company 13 Personalized Medicines In Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 172: Company 13 Personalized Medicines In Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 173: Company 13 Personalized Medicines In Oncology Market Net Sales Share, By Geography, 2018 (%)
Figure 174: Company 14 Personalized Medicines In Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 175: Company 14 Personalized Medicines In Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 176: Company 14 Personalized Medicines In Oncology Market Net Sales Share, By Geography, 2018 (%)
Figure 177: Company 15 Personalized Medicines In Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 178: Company 15 Personalized Medicines In Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 179: Company 15 Personalized Medicines In Oncology Market Net Sales Share, By Geography, 2018 (%)